Krempa David 4

What Happened

• David Krempa, Chief Business Officer of Eton Pharmaceuticals (ETON), received a grant of 10,000 restricted stock units (RSUs) on 2026-06-26. The grant price is listed as $0.00 (i.e., an award/compensation grant), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-06-26; Form 4 filed: 2026-06-30 (filed within the usual two business-day window for Form 4s following a 6/26 grant).
• Instrument: 10,000 restricted stock units (derivative award), grant price $0.00; reported value at grant: $0 (compensatory award).
• Vesting: RSUs vest in four equal annual installments beginning June 26, 2027, contingent on continued employment (see footnote F2).
• Footnote F1: Each RSU represents a contingent right to receive one share of ETON common stock upon vesting.
• Shares owned after the transaction: Not specified in this Form 4.
• Filing authority remark: The reporting person authorized a designated filer to submit this Form 4 on their behalf.

Context

• RSUs are a form of compensation rather than an immediate stock purchase; they convert into actual shares only if/when they vest. This grant does not represent an immediate purchase or sale, and there was no immediate taxable sale or cashless exercise reported.
• For retail investors: awards like this signal management compensation and potential future dilution if and when RSUs vest and shares are issued; they are not a direct bullish/bearish market action by the insider.